Cardiff University’s European Cancer Stemcell Research Institute, Velindre NHS Trust and Cancer Research UK will be holding a Cancer Research Open Day on Saturday 24th October at the Hadyn Ellis Building, Maindy Road (posters attached).
This public event will showcase the diverse, cutting-edge cancer research taking place across Cardiff and attendees from across Wales are welcome. The event is aimed primarily at members of the public but visitors will meet cancer scientists, doctors and nurses, go behind the scenes on lab tours, learn about local research through talks and interactive demos and create some biological artwork with local textile artist, Lisa Porch.
Attendance is free and visitors can register their interest at https://www.eventbrite.co.uk/e/cardiff-cancer-research-open-day-2015-tickets-18114580197.
For further information please see the attached posters.
£10m to conserve antibiotics for future generations
Thursday 24th September
18:00-20:00, Life Sciences Hub, 3 Assembly Square, Cardiff. Wales. CF10 4PL
Refreshments will be provided
Nesta and Life Sciences Hub Wales would like to invite you to come and find out more about the £10m Longitude Prize’s fascinating 300-year history, last year’s BBC Horizon vote and what you need to do to win the Prize.
The Longitude Prize is a historic challenge that aims to conserve antibiotics for future generation. The challenge is to develop a cheap, accurate, rapid and easy-to-use, point-of-care test that will identify when antibiotics are needed and, if they are, which ones to use.
The Longitude Prize was opened last year and will run until December 2019 or until a winner is found.
Find out more about how to win the Longitude Prize – sign up now
The event will be hosted by Adam Price
You will hear from:
Dr Tracey Cooper
Chief Executive – Public Health Wales
Professor Chris Butler
Professor of Primary Care Medicine and Longitude Prize Judging Panel member
Professor Jim McLaughlin OBE
Professor in the University of Ulster School of Engineering & Chief Technology Officer – Zensor
Cardiff University are looking to support a number of research projects through innovative crowdfunding company FutSci. Crowdfunding, in its simplest form, is a way of raising funds by asking a large number of people to contribute a relatively small amount of money. Futsci specialises in funding biomedical research through crowdfunding and provide the opportunity for individual to support specific research projects.
For more information, please visit their website, https://www.futsci.com
Anti Microbial Resistance
Antimicrobial resistance is a growing public health issue that threatens to undermine the treatment of an increasing range of infections caused by bacteria, viruses and fungi. Many of the most commonly used antimicrobials are becoming less effective with bacteria, viruses and fungi naturally adapting and becoming increasingly resistant to medicines used to treat the infections they cause.
This is a global problem that the Work Economic Forum and World Health Organisation have both identified as a major public health problem.
The issue has also been raised by the UK’s Chief Medical Officer and resulted in the Department of Health releasing a Five Year Antimicrobial Resistance Strategy (2013-18).
Academics from across Wales have a long track record of research into antimicrobial resistance and are working together to address key challenges in the following areas:
Alternative Approaches to Treating Bacterial Infection
Development of Novel Therapeutics
Development of Diagnostic Devices.
The consortium includes members from the following Welsh universities:
Aberystwyth, Bangor, Cardiff and Swansea.
If you are interested in joining the forum or finding out more, please email us email@example.com
The Network has recently awarded the following Round 3 Research Projects and Studentships:
Dr Gwenin, A rapid point of care system to manage/monitor drug treatment in therapeutically relevant mycobacterial infections
Prof O’Donnell, Development of new prothrombotic lipids for haemostatic applications
Prof Hall, Investigating the potential of the sphingosine-1-phosphate receptor 1 modulators for the treatment of psychiatric disorders.
Prof Piguet, Anti-viral activity of ProTide derivatives on human T cells
Dr Rozanowska, Novel modulators of the visual cycle for treatment of retinal degenerations
Dr Kidd, Investigating a novel therapy for Alzheimer’s disease in a mouse model of amyloid pathology
Dr Clarkson, Sensitizing to radiotherapy: ore-clinical evaluation of a novel indication for adjuvant bcl3i
Prof Dale, Establishing a screen for the WNT-STOP mitotic signalling pathway
Prof Wilkinson, Expression and activity determination of novel cloned antibiofilm peptides
Dr Westwell, Advancing analogues of a novel cFLIP inhibitor which sensitises breast cancer cells and cancer stem cells to TRAIL
Dr Heard, Towards the repurposing existing of topical antimicrobials by ligand complexation.
Prof Hoffmann, Repositioning histone methyltransferase inhibitors as next generation anthelmintics.
Prof Mur, Exploiting natural products from Hops (Humulus lupulus) to suppress tuberculosis.
Prof Sheldon, Manipulation of squalene synthase to limit bacterial infections.
Dr Howell, Treating Progressive Multiple Sclerosis Using A Novel Neuroprotective And Anti-Inflammatory approach.
Dr Del Sol, Companion diagnostic development guides Antibody-Drug Conjugate formulation: Implications for patient stratification and precision medicine.
Dr Cai, Combining carbon monoxide (CO)-releasing molecules with anti-VEGF therapy for triple-negative breast cancer therapy.
Prof Doak, Design and evaluation of an antibody-drug conjugate for prostate cancer treatment.
Prof Brophy, Towards validation of an immune suppressor protein from liver fluke as a drug target.
Prof Triantafilou, Peptides derived from Yersinia pestis V antigen as novel therapeutic interventions for sepsis.
Prof Doak, Mechanistic evaluation of the impact of superparamagnetic iron oxide nanoparticles conjugated with drugs (SPIONd) on intracellular signalling/homeostatic mechanisms.
Dr Creevey, Computational approaches to mining the rumen micro biome for novel antimicrobials.
Dr Gwenin, Testing a novel chemotherapy delivery system using two dinitrobenzamide mustard prodrugs.
The AMR cross-council initiative has launched a new call under theme 2 – “Accelerating therapeutic and diagnostic development”.
MRC, BBSRC, EPSRC, and ESRC are supporting this call and the MRC is managing it on behalf of the funding partners.
The focus of the call is to:
- Refresh the pipeline for human and animal antibiotics;
- Develop new non-drug based treatments for bacterial infections (vaccines, immunotherapies, probiotics, prebiotics, phages, amongst others);
- Improve the efficacy of existing drugs through effective dosing strategies to minimise development of resistance and/or develop more targeted delivery methods;
- Accelerate the scale-up and manufacture of novel antibiotics and vaccines;
- Underpin the development of rapid, point of care diagnostics to enable the most appropriate therapy/intervention to be chosen;
- Develop innovative diagnostics data linkages for community settings to monitor spread; and
- Consider the real world issues that will affect the development and utilisation of new treatments and diagnostics
Partnership between industry and academia is actively encouraged under this initiative.
The call has two funding modes:
- Collaborative grants – ~£3m each for 4-5 years, multidisciplinary in nature across more than one research organisation
- Innovative grants – ~£200k each over 12-24 months, highly innovative, high risk/high gain
Deadline for submission is 4 June 2015.
Please circulate widely to your communities and direct them to this webpage:
MRC: Ghada Zoubiane / Ruth Kelly firstname.lastname@example.org
BBSRC: Sian Rowland: email@example.com
EPSRC: Victoria Marlow: firstname.lastname@example.org
ESRC: Naomi Beaumont: Naomi.Beaumont@esrc.ac.uk
Our call has now closed and we have received and acknowledged a record number of applications – 83 in total! Thank you for applying.
For information, the board will be meeting on 29th and 30th April to discuss applications and award successful ones.
If you have any queries in the mean time, please contact us email@example.com